Asset profile
ozanimod · Zeposia
Small molecule
Evidence outlook
Approved: Multiple Sclerosis, Ulcerative Colitis (label: moderately to severely active UC who have had an inadequate response, lost response, or were...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
107 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 100 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ozanimod (Zeposia): this drug | Approved | Small molecule | S1P receptor | ||
| Etrasimod (Velsipity) | Approved | Small molecule | S1P receptor | ||
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | ||
| Mayzent | Approved | Small molecule | S1P receptor | ||
| Ponesimod | Approved | Small molecule | S1P receptor | ||
| Tascenso ODT | Approved | Small molecule | S1P receptor | ||
| Amiselimod | Phase 2 | Small molecule | S1P receptor | ||
| Tamuzimod | Phase 2 | Small molecule | S1P receptor | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha | ||
| Adalimumab-Aqvh (Yusimry) | Approved | — | TNF-alpha | ||
| Adalimumab-Atto (Amjevita) | Approved | — | TNF-alpha |
…and 92 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
June 2027 (1)
What to watch
2028 (2)
2031 (1)
April 2031 (1)
What to watch
2032 (1)
July 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.